James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Moore, D. F., R. Pazdur, J. L. Abbruzzese, J. A. Ajani, D. W. Dubovsky, J. L. Wade, R. J. Belt, C. Mangold, B. Bready, and R. J. Winn. “Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma..” Ann Oncol 5, no. 3 (March 1994): 286–87. https://doi.org/10.1093/oxfordjournals.annonc.a058810.

PMID
8186177
Full Text

Lenzi, R., P. Frost, and J. L. Abbruzzese. “Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines..” Anticancer Res 14, no. 1A (January 1994): 247–51.

PMID
7513143
Scholars@Duke

Moore, D. F., R. Pazdur, and J. L. Abbruzzese. “Phase II trial of intravenous melphalan in advanced colorectal carcinoma..” Invest New Drugs 12, no. 2 (1994): 133–36. https://doi.org/10.1007/bf00874443.

PMID
7860230
Full Text

Lenzi, R., P. Frost, and J. L. Abbruzzese. “Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.” Anticancer Research 14, no. 1 A (1994): 247–51.

Scholars@Duke

Fuhrman, G. M., C. Charnsangavej, J. L. Abbruzzese, K. R. Cleary, R. G. Martin, C. J. Fenoglio, and D. B. Evans. “Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms..” Am J Surg 167, no. 1 (January 1994): 104–11. https://doi.org/10.1016/0002-9610(94)90060-4.

PMID
7906097
Full Text

Jones, D. V., Y. Z. Patt, J. A. Ajani, J. Abbruzzese, C. H. Carrasco, C. Charnsangavej, B. Levin, and S. Wallace. “A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver..” Cancer 72, no. 9 (November 1, 1993): 2560–63. https://doi.org/10.1002/1097-0142(19931101)72:9<2560::aid-cncr2820720908>3.0.co;2-e.

PMID
8402476
Full Text

Bar-Eli, M., J. L. Abbruzzese, D. Lee-Jackson, and P. Frost. “p53 gene mutation spectrum in human unknown primary tumors..” Anticancer Res 13, no. 5A (September 1993): 1619–23.

PMID
8239543
Scholars@Duke

Lee-Jackson, D., J. L. Abbruzzese, and M. Bar-Eli. “Artifactual frame-shift p53 mutation at codon 249 detected with the Cyclist DNA sequencing method..” Biotechniques 15, no. 3 (September 1993): 363–64.

PMID
8217139
Scholars@Duke

Abbruzzese, J. L., R. Lenzi, M. N. Raber, S. Pathak, and P. Frost. “The biology of unknown primary tumors..” Semin Oncol 20, no. 3 (June 1993): 238–43.

PMID
8503019
Scholars@Duke

Ajani, J. A., J. L. Abbruzzese, A. B. Markowitz, Y. Z. Patt, and K. Daugherty. “Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma..” Invest New Drugs 11, no. 1 (February 1993): 67–69. https://doi.org/10.1007/bf00873914.

PMID
8349439
Full Text

Pages